Peptide News Digest

Parabilis $476M Peptide IPO, Petrelintide ZUPREME-1 Amylin Data, Survodutide SYNCHRONIZE-1 Obesity, Verdiva Amylin Pipeline, AstraZeneca Elecoglipron, ADA 2026 Eve

ADA's eve: Parabilis prices a $476M peptide IPO, plus pre-conference data from petrelintide, survodutide, Verdiva, and elecoglipron.

6 stories · Covering industry, clinical-trials, research

Editor's Note

The day before the American Diabetes Association meeting opened, the obesity field emptied its pre-conference notebook while the late-breaking data stayed embargoed until Friday evening. The throughline was the amylin and oral-peptide push that is reshaping a field GLP-1 built: Roche and Zealand's petrelintide leaned on tolerability, Verdiva brought an oral amylin and a co-agonist, and Boehringer's survodutide pressed its glucagon angle. Away from obesity, Parabilis priced a Nasdaq IPO of up to $476 million on a beta-catenin-blocking helical peptide, a reminder that the modality's reach extends well past metabolism. None of the embargoed numbers are public yet; what June 4 offered was the lineup, and starting June 5 the ADA podium turns these press releases into data.

Industry

Parabilis Medicines Prices Nasdaq IPO at Up to $476M to Push Helical Peptide Zolucatetide Toward Phase 3 in Desmoid Tumors

Parabilis Medicines (formerly FogPharma) set terms June 4 for a Nasdaq IPO under ticker PBLS: 25 million shares at $17-19, raising about $413 million, or up to $476 million if underwriters exercise the overallotment. Proceeds fund its lead asset zolucatetide, a cell-penetrating helical peptide that blocks beta-catenin, through dose expansion and into Phase 3 for desmoid tumors, plus studies in familial adenomatous polyposis and hepatocellular carcinoma. The offering follows a $75 million Regeneron investment tied to a collaboration worth up to $2.3 billion for antibody-helicon conjugates.

#parabilis-medicines #zolucatetide #helical-peptide #ipo #desmoid-tumors #beta-catenin
Clinical Trials

Roche and Zealand's Petrelintide Heads to ADA 2026 as a Late-Breaker: 10.7% Weight Loss and No Vomiting at the Top Dose in Phase 2 ZUPREME-1

Roche will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide as an ADA 2026 late-breaker, with a June 8 investor event. In 493 adults with overweight or obesity (mean BMI 37), once-weekly petrelintide produced up to 10.7% mean weight loss at week 42 versus 1.7% on placebo, with treatment discontinuation of 4.8% versus 4.9% on placebo and no vomiting or GI-related discontinuations at the maximally effective dose. That tolerability is the amylin class's central pitch against the incretins.

#petrelintide #zealand-pharma #roche #amylin #zupreme-1 #obesity #ada-2026
Clinical Trials

Boehringer and Zealand's Survodutide Brings Full SYNCHRONIZE-1 Obesity Data to ADA 2026: 16.6% Weight Loss at 76 Weeks

Full Phase 3 SYNCHRONIZE-1 results for the glucagon/GLP-1 dual agonist survodutide are set for ADA 2026, detailing the obesity readout first toplined in April. In adults with obesity or overweight without type 2 diabetes, survodutide produced up to 16.6% mean weight loss at 76 weeks versus 3.2% on placebo, with up to 85.1% of treated patients losing at least 5% of body weight. The full dataset puts survodutide's glucagon component, which adds energy expenditure and liver-fat effects, in front of the field that gathers in New Orleans.

#survodutide #boehringer-ingelheim #zealand-pharma #synchronize-1 #obesity #glp-1-glucagon #ada-2026
Research

Verdiva Bio Brings Oral Amylin VRB-103 and a GLP-1/Amylin Co-Agonist to ADA 2026 With Preclinical Data

Verdiva Bio will present two posters at ADA 2026 on its obesity pipeline: VRB-103, a once-weekly oral amylin-receptor-selective analog, and VRB-104, a unimolecular GLP-1 plus amylin co-agonist. The preclinical data extend the amylin and oral-peptide push from a well-funded newer entrant, as the obesity field broadens beyond incretin monotherapy toward amylin-based and oral approaches.

#verdiva-bio #vrb-103 #vrb-104 #amylin #oral-peptides #obesity #ada-2026
Clinical Trials

AstraZeneca and Eccogene's Oral GLP-1 Elecoglipron Adds a China Phase 1b Late-Breaker to Its ADA 2026 Slate Alongside VISTA and SOLSTICE

Eccogene and AstraZeneca will present multiple datasets for the oral small-molecule GLP-1 receptor agonist elecoglipron (AZD5004/ECC5004) at ADA 2026 on June 7-8, including a late-breaking Phase 1b study conducted in China, plus the Phase 2b VISTA trial in obesity (which met its primary endpoints) and the SOLSTICE Phase 2b trial in type 2 diabetes. The slate deepens the oral-GLP-1 contest forming below Lilly's orforglipron.

#elecoglipron #azd5004 #astrazeneca #eccogene #oral-glp-1 #vista #ada-2026
Industry

ADA 2026 Late-Breaker Embargo Lifts June 5: MetaVia DA-1726, Structure Aleniglipron, Hengrui-Kailera, and the Lilly-Novo Symposia

The American Diabetes Association's late-breaking abstracts release Friday, June 5 at 6:30 p.m. Central, opening the meeting's data flood in New Orleans (June 5-8). Queued readouts include MetaVia's dual oxyntomodulin DA-1726 and GPR119 agonist vanoglipel, Structure's oral aleniglipron, and Hengrui and Kailera's oral incretins, alongside the Phase 3 retatrutide symposium June 6 and the orforglipron symposium June 8. Novo Nordisk holds an R&D investor event June 7.

#ada-2026 #metavia #da-1726 #aleniglipron #late-breaking-abstracts #new-orleans